logo

For the Inventor, By the Inventor

Corona, CA, United States of America

Watson Pharmaceuticals, Inc.


USPTO Granted Patents = 27

% Expired Patents = 25.9



Trademarks = 38

Forward Citations = 612

Loading Chart...
Loading Chart...

39 inventors (with patents filed for the assignee):

goldMedal Avinash Nangia (5 out of 24 patents)

silverMedal Charles D Ebert (5 out of 44 patents)

bronzeMedal Srinivasan Venkateshwaran (4 out of 38 patents)

4.  Unchalee Kositprapa (4 out of 15 patents)

5.  John R Cardinal (4 out of 6 patents)

6.  Robert I Goldfarb (4 out of 5 patents)

7.  Danyi Quan (4 out of 10 patents)

8.  Thomas Ho (3 out of 4 patents)

9.  Nilesh H Parikh (3 out of 3 patents)

10.  Steven W Sanders (2 out of 11 patents)

11.  Theresa Rosario-Jansen (2 out of 3 patents)

12.  Norman A Mazer (2 out of 4 patents)

13.  David Chung Hsia (2 out of 2 patents)

14.  Domingo Yap Tan (2 out of 2 patents)

15.  Fredric B Weihmuller (2 out of 2 patents)


Core Competencies:
Oxybutynin
Metronidazole
Tranexamic Acid
Biguanide
Thiazolidinedione
Progesterone
Transdermal Delivery
Pressure Sensitive Adhesive
Conjugated Estrogens
Androgenic Steroids
Oral Delivery
Antioxidant Composition

27 patents:

1. 9259388 - Method for treating overactive bladders and a device for storage and administration of topical oxybutynin compositions (2016-02-16),
2. 9198858 - Methods of treating bacterial vaginosis with aqueous-based metronidazole gel formulations (2015-12-01),
3. 8597683 - Modified release tranexamic acid formulation (2013-12-03),
4. 8470368 - Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative (2013-06-25),
5. 8309125 - Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative (2012-11-13),
6. 8309104 - Oral controlled release formulation for sedative and hypnotic agents (2012-11-13),
7. 8084058 - Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative (2011-12-27),
8. 7959946 - Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative (2011-06-14),
9. 7785627 - Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative (2010-08-31),
10. 7338667 - Pharmaceutical formulation (2008-03-04),
11. 7186706 - Administration of non-oral androgenic steroids to women (2007-03-06),
12. 7179483 - Compositions and methods for transdermal oxybutynin therapy (2007-02-20),
13. 6866865 - Dosage forms and methods for oral delivery of progesterone (2005-03-15),
14. 6743441 - Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy (2004-06-01),
15. 6730318 - Transdermal delivery devices containing polydiorganosiloxane polymers to regulate adhesive properties (2004-05-04),
Watson Pharmaceuticals, Inc. is a prominent player in the pharmaceutical industry, specializing in the development and manufacturing of generic and branded medications. The company focuses on a diverse range of therapeutic areas, including oncology, cardiovascular health, and central nervous system disorders. With its headquarters in Corona, California, Watson is dedicated to advancing healthcare through innovative drug solutions and is committed to improving patient outcomes across various markets.
Profile summary based on public USPTO records.

logo

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

Watson Pharmaceuticals, Inc.
27 Patents

#5 in Corona, CA

#2,931 in California

#12,405 in US

#23,968 in the World

Corona, CA (US)
Corona, CA, United States of America

Watson Pharmaceuticals, Inc.

Forward Citations = 612

39 inventors:

goldMedal Avinash Nangia (5 out of 24 patents)

silverMedal Charles D Ebert (5 out of 44 patents)

bronzeMedal Srinivasan Venkateshwaran (4 out of 38 patents)

4.  Unchalee Kositprapa (4 out of 15 patents)

5.  John R Cardinal (4 out of 6 patents)

Please report any incorrect information to [email protected]
Loading…